SOURCE-LINKED STUDY SUMMARY
Current and forthcoming pharmacotherapies for adolescent obesity: Evidence-based review.
Abstract summarizedQuality not appraised
- What was studied
- A short review examined current and emerging medicines for adolescent obesity.
- Who / model studied
- Included evidence focused on randomized trials and meta-analyses in adolescents aged 12–18, with studies lasting more than 12 weeks. No pooled participant count is provided.
- Studied dose & schedule
- Dose and schedule have not yet been extracted for this summary.
- What the study found
- The review reports a 16.1% reduction in body mass index with semaglutide. It also identifies cost and unequal access as barriers.
- Limitations & context
- Evidence for tirzepatide and CagriSema in adolescents remained limited. The authors call for longer-term, comparative and paediatric safety studies.
Read summary source ↗ · Prepared 9/15/2026 · AI-assisted, source-based summary
Review record & corrections
Summary prepared: . Source scope: abstract. This is an AI-assisted source summary, not an independent clinician sign-off.
No public field-by-field revision history is available for this card yet. The date above is the summary date, not proof that every field was updated then.
Inspect the source · Correction policyResearch findings apply to the population and conditions studied. This educational summary is not a treatment recommendation or a formal assessment of study quality.
Original publication ↗ · DOI: 10.5409/wjcp.118730